

Gavi Alliance Board Meeting

29-30 November 2017 Crowne Plaza Hotel, Vientiane, Lao PDR

Quorum: 14

Declarations of Interest

Declarations

Section 5.2 of the Conflict of Interest Policy states, "Annually, each member of the Board (including alternate Board members and Committee delegates)...shall complete and submit a conflict of interest form to be distributed by the Managing Director, Law and Governance." The following declarations were made by members of the Board on their most recent annual statements:

Board members:

Member	Organisational Interests	Financial/Personal/Advisor Int/ Others
Ngozi Okonjo-Iweala, Chair	None	Gavi-appointed special adviser
Gunilla Carlsson, Vice Chair	None	Geneva Center Security Policy (Associate Fellow) African Development Band (Special Advisor) NGS Group AB (Board) Boxholms Skrgar AB (Board) Kolmarden Charity (Board Chair) Tundra (Board) Gavi-appointed special adviser
Peggy Hamburg	None	Joint Coordinating Group (Chair) Coalition for Epidemic Innovations (CEPI) (Board)
Yifei Li	None	Man Group (Country Chair) Rockefeller Foundation (Board) Jackson Institute for Global Affairs, Yale University (Board)
Helen Rees	None	None
William H. Roedy	None	None
Richard Sezibera	None	Gavi-appointed special adviser
David Sidwell	None	Chubb Limited (Board) UBS (Board, Risk and Governance Committees)
Stephen Zinser	None	Roxbury Asset Management (CEO and Co-CIO)
Orin Levine	Bill & Melinda Gates Foundation	PATH (Spouse)
Tim Evans	The World Bank	None

Member	Organisational Interests	Financial/Personal/Advisor Int/ Others
Shanelle Hall	UNICEF	None
Ummy Ally Mwalimu	Government of Tanzania	Gav-appointed special adviser
Myint Htwe	Government of Myanmar	None
Bahar Idriss Abugarda	Government of Sudan	Gavi-appointed special adviser
Edna Yolani Bátres	Government of Honduras	Gavi-appointed special adviser
Raymonde Goudou Coffie	Government of Côte d'Ivoire	Gavi-appointed special adviser
Jan Paehler	EC (GER/FRA/LUX/EC/IRL)	Global Fund (Board, Ethics and Governance Committee)
Amy Baker	CAN (CAN/IT/SP)	None
Reina Buijs	NED (NOR/NED/SWE)	None
Daniel Graymore	UK (UK/Qatar)	UNICEF (Spouse)
Blair Exell	AUS (USA/AUS/JPN/KOR)	None
Susan Silbermann	Int'l Federation of Pharmaceutical Manufacturers & Associations	President & General Manager Pfizer Vaccines, Pfizer Inc.
Sai Prasad	Developing Countries Vaccine Manufacturers Network	President, Bharat Biotech Intl. Ltd; Director, RCC Laboratories; Director, Innova Agri Bio Park; Director, Odisha Biotech Park
Clarisse Loe Loumou	CSOs	Gavi-appointed special adviser
Oyewale Tomori	Research & Tech. Health Inst	None
Seth Berkley (non-voting)	None	Gilead Sciences; Acumen Fund; Columbia, Brown and NY Univ.

Alternate Board members:

Member	Organisational Interests	Financial/Personal/Advisor Int/ Others
Violaine Mitchell	Bill & Melinda Gates Foundation	None
Rama Lakshminarayanan	The World Bank	None
Ted Chaiban	UNICEF	None
Jean-Marie Okwo-Bele	WHO	None
Yifru Berhan Mitke	Government of Ethiopia	Gavi-appointed special adviser
Bounkong Syhavong	Government of Lao PDR	None
Muhammad Ayub Sheikh	Government of Pakistan	Gavi-appointed special adviser
Sergey Khachatryan	Government of Armenia	Gavi-appointed special adviser
Félix Kabange	Government of Democratic Republic of Congo	Gavi-appointed special adviser
Jean-Francois Pactet	FRA (GER/FRA/LUX/EC/IRL)	None
Angela Santoni	IT (CAN/IT/SP)	None
Anna Hamrell	SWE (NOR/NED/SWE	None
Jason Lane	UK (UK/Qatar)	None
Irene Koek	USA (USA/AUS/JPN/KOR))	None
John Roberts	Int'l Federation of Pharmaceutical Manufacturers & Associations	VP, Vaccines, Pfizer Inc.
Mahima Dalta	Developing Countries Vaccine Manufacturers Network	Biological E Limited (Managing Director)
Craig Burgess	CSOs	JSI Training and Research Institute Gavi-appointed special adviser
Katherine O' Brien	Research & Tech. Health Inst	Member of Vaccine Advisory Committee (WHO), University of Maryland (Employee) and University receives funding from Pfizer, GSK, Merck, BMGF, and Gov of USA

Participation

Section 6.2 of the Policy states, "During the course of a Board or Board Committee meeting, a GAVI Person with an actual, perceived or potential Conflict of Interest shall disclose the interest to the Chair of the meeting as soon as possible upon learning of a possible Conflict of Interest and in no event later than at the beginning of discussion of the pertinent agenda item."

Section 6.3 states, "It shall be the prerogative of the Chair of the meeting, in consultation with the Managing Director, Law and Governance, as appropriate, to determine the scope and level of a conflicted person's participation in the discussion and the necessity of recusal from voting given the type of interest disclosed. The minutes of the meeting shall reflect the conflicted member's disclosure and whether the conflicted member participated in the discussion and/or abstained from voting."